AI Biomedicine Service Market Report – Research, Industry Analysis Reports and Market Demands

Global AI Biomedicine Service Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global AI Biomedicine Service Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of AI Biomedicine Service by Company Revenue
- 3.2.2 Top 3 AI Biomedicine Service Players Market Share in 2025
- 3.2.3 Top 6 AI Biomedicine Service Players Market Share in 2025
3.3 AI Biomedicine Service Market: Overall Company Footprint Analysis
- 3.3.1 AI Biomedicine Service Market: Region Footprint
- 3.3.2 AI Biomedicine Service Market: Company Product Type Footprint
- 3.3.3 AI Biomedicine Service Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global AI Biomedicine Service Consumption Value and Market Share by Type (2021-2026)
4.2 Global AI Biomedicine Service Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global AI Biomedicine Service Consumption Value Market Share by Application (2021-2026)
5.2 Global AI Biomedicine Service Market Forecast by Application (2027-2032)

6 North America

6.1 North America AI Biomedicine Service Consumption Value by Type (2021-2032)
6.2 North America AI Biomedicine Service Market Size by Application (2021-2032)
6.3 North America AI Biomedicine Service Market Size by Country
- 6.3.1 North America AI Biomedicine Service Consumption Value by Country (2021-2032)
- 6.3.2 United States AI Biomedicine Service Market Size and Forecast (2021-2032)
- 6.3.3 Canada AI Biomedicine Service Market Size and Forecast (2021-2032)
- 6.3.4 Mexico AI Biomedicine Service Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe AI Biomedicine Service Consumption Value by Type (2021-2032)
7.2 Europe AI Biomedicine Service Consumption Value by Application (2021-2032)
7.3 Europe AI Biomedicine Service Market Size by Country
- 7.3.1 Europe AI Biomedicine Service Consumption Value by Country (2021-2032)
- 7.3.2 Germany AI Biomedicine Service Market Size and Forecast (2021-2032)
- 7.3.3 France AI Biomedicine Service Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom AI Biomedicine Service Market Size and Forecast (2021-2032)
- 7.3.5 Russia AI Biomedicine Service Market Size and Forecast (2021-2032)
- 7.3.6 Italy AI Biomedicine Service Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific AI Biomedicine Service Consumption Value by Type (2021-2032)
8.2 Asia-Pacific AI Biomedicine Service Consumption Value by Application (2021-2032)
8.3 Asia-Pacific AI Biomedicine Service Market Size by Region
- 8.3.1 Asia-Pacific AI Biomedicine Service Consumption Value by Region (2021-2032)
- 8.3.2 China AI Biomedicine Service Market Size and Forecast (2021-2032)
- 8.3.3 Japan AI Biomedicine Service Market Size and Forecast (2021-2032)
- 8.3.4 South Korea AI Biomedicine Service Market Size and Forecast (2021-2032)
- 8.3.5 India AI Biomedicine Service Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia AI Biomedicine Service Market Size and Forecast (2021-2032)
- 8.3.7 Australia AI Biomedicine Service Market Size and Forecast (2021-2032)

9 South America

9.1 South America AI Biomedicine Service Consumption Value by Type (2021-2032)
9.2 South America AI Biomedicine Service Consumption Value by Application (2021-2032)
9.3 South America AI Biomedicine Service Market Size by Country
- 9.3.1 South America AI Biomedicine Service Consumption Value by Country (2021-2032)
- 9.3.2 Brazil AI Biomedicine Service Market Size and Forecast (2021-2032)
- 9.3.3 Argentina AI Biomedicine Service Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa AI Biomedicine Service Consumption Value by Type (2021-2032)
10.2 Middle East & Africa AI Biomedicine Service Consumption Value by Application (2021-2032)
10.3 Middle East & Africa AI Biomedicine Service Market Size by Country
- 10.3.1 Middle East & Africa AI Biomedicine Service Consumption Value by Country (2021-2032)
- 10.3.2 Turkey AI Biomedicine Service Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia AI Biomedicine Service Market Size and Forecast (2021-2032)
- 10.3.4 UAE AI Biomedicine Service Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 AI Biomedicine Service Market Drivers
11.2 AI Biomedicine Service Market Restraints
11.3 AI Biomedicine Service Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 AI Biomedicine Service Industry Chain
12.2 AI Biomedicine Service Upstream Analysis
12.3 AI Biomedicine Service Midstream Analysis
12.4 AI Biomedicine Service Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global AI Biomedicine Service market size was valued at US$ 4253 million in 2025 and is forecast to a readjusted size of US$ 7704 million by 2032 with a CAGR of 8.8% during review period.
AI biomedicine service represents the deep application of artificial intelligence technology in the biomedical field, aiming to accelerate new drug development, optimize disease diagnosis and treatment plans through advanced technologies such as big data analysis and machine learning. This service encompasses multiple aspects, from drug discovery and clinical trial design to patient management, significantly improving the efficiency and accuracy of biomedical research and development. By deeply mining massive medical data, ai can identify potential biomarkers, predict disease progression, and provide personalized treatment plans for patients. Additionally, ai assists doctors in diagnosing complex diseases, reducing misdiagnosis rates, and enhancing the quality of medical services. With continuous technological advancements, ai biomedicine service is gradually transforming the landscape of the biomedical industry, bringing more health benefits to patients.
From a multi-dimensional classification and parameterization perspective, the market can be segmented by service focus (AI drug discovery, AI antibody/biologic discovery, AI pathology and biomarker services, AI omics analytics), by delivery model (platform-as-a-service, fee-for-service, co-development partnerships, or risk-sharing milestone models), and by data modality (chemical structures, protein structures, imaging pathology data, genomics, transcriptomics, and multi-omics). Key performance parameters used by customers include hit identification success rates, lead optimization cycles, reduction in wet-lab iterations, model generalizability across targets, and the ability to integrate proprietary datasets securely.
The industry value chain begins upstream with data generation sources such as high-throughput screening labs, biobanks, sequencing providers, and pathology laboratories, alongside cloud and computing infrastructure suppliers. Midstream players are AI Biomedicine Service providers that combine proprietary algorithms, curated datasets, and domain expertise to deliver discovery or analysis services. Downstream customers include pharmaceutical companies, biotech startups, and, increasingly, CROs and CDMOs integrating AI into their service portfolios. Strategic partnerships and long-term collaborations are common, often embedding AI services deeply into clients’ R&D workflows.
From a profitability perspective, AI Biomedicine Services generally exhibit attractive gross margins, typically in the 60–80% range, reflecting their software- and data-driven nature. Margins vary by model: platform subscriptions and recurring service contracts achieve higher margins, while project-based discovery services see lower margins due to scientific labor and validation costs. Market momentum is driven by rising R&D costs, pressure to improve pipeline productivity, and growing acceptance of AI-derived insights by regulators and pharma partners. Key trends include consolidation between AI platforms and CROs, expansion from discovery into preclinical and translational stages, and increasing use of outcome-linked and co-development revenue models.
This report is a detailed and comprehensive analysis for global AI Biomedicine Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global AI Biomedicine Service market size and forecasts, in consumption value ($ Million), 2021-2032
Global AI Biomedicine Service market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global AI Biomedicine Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global AI Biomedicine Service market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for AI Biomedicine Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global AI Biomedicine Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abcellera Biologics, Evotec, Atomwise, XtalPi, PathAI, Paige AI, HotSpot Therapeutics, Scorpion Therapeutics, Charm Therapeutics, LifeMine Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
AI Biomedicine Service market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
AI-driven Drug Discovery Services
AI-based Preclinical Research Services
AI-enabled Clinical Trial Services
AI Biomarker & Companion Diagnostic Services
Others
Market segment by Data Type & Modality
Genomics & Multi-omics AI Services
Medical Imaging & Digital Pathology AI Services
Chemical & Molecular Structure AI Services
Clinical & EHR Data AI Services
Others
Market segment by Service Delivery Model
Project-based AI Research Services
Subscription-based AI Platforms (Service Mode)
AI-as-a-Service (API / Cloud-based)
Others
Market segment by Application
Pharmaceutical & Biotech Companies
CRO / CDMO-oriented Companies
Academic & Research Institutes
Others
Market segment by players, this report covers
Abcellera Biologics
Evotec
Atomwise
XtalPi
PathAI
Paige AI
HotSpot Therapeutics
Scorpion Therapeutics
Charm Therapeutics
LifeMine Therapeutics
C4XD Discovery
Wave Life Sciences
Westlake Omics
IIpharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe AI Biomedicine Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of AI Biomedicine Service, with revenue, gross margin, and global market share of AI Biomedicine Service from 2021 to 2026.
Chapter 3, the AI Biomedicine Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and AI Biomedicine Service market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of AI Biomedicine Service.
Chapter 13, to describe AI Biomedicine Service research findings and conclusion.

Buy now